FindTrial
Sign In

A retrospective study of the efficacy of ablation combined with immune checkpoint inhibitors in the treatment of liver metastases

A retrospective study of the efficacy of ablation combined with immune checkpoint inhibitors in the treatment of liver metastases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081797
Enrollment
Unknown
Registered
2024-03-12
Start date
2024-03-18
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver metastasis

Interventions

Control group (PD-1 inhibitor therapy only):None
Combined therapy group (combined ablation with PD-1 inhibitor therapy):None

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Metastatic hepatocellular carcinoma of primary malignant tumors confirmed by pathohistology; (2) Single tumors with maximum diameter = 5 cm without vascular or biliary invasion; multiple tumors with the number of foci < 3, maximum diameter = 3 cm without vascular or biliary invasion; (3) Vital signs stable, ECOG 0-1; (4) Aged 18 ~ 80 years old; (5) Receiving treatment with immune checkpoint inhibitor therapy or combination of ablation therapy;

Exclusion criteria

Exclusion criteria: (1) Primary hepatic malignancy; (2) Incomplete or missed clinical baseline information;

Design outcomes

Primary

MeasureTime frame
progression-free survival (PFS) ;1-year survival;—

Secondary

MeasureTime frame
Overall survival;Disease Control Rate(DCR);6-month Disease Free Survival (6-month DFS);—

Countries

China

Contacts

Public ContactZhang fujun

Sun Yat-sen University Cancer Center

zhangfj@sysucc.org.cn+86 138 2622 2266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026